ZEE Business
ZEE BUSINESS
हिंदी में पढ़ें  हिंदी में पढ़ें
Live TV
Live TV
  • Home
  • Personal Finance
    • PPF
    • Mutual Funds
    • Income tax
    • EPFO
    • Income Tax Calculator
    • Personal Loan Calculator
    • Car Loan Calculator
    • Home Loan Calculator
    • SIP calculator
    • SWP Calculator
    • MF Returns Calculator
    • Lumpsum Calculator
  • India
    • Companies
    • Property
    • Startups
    • Uidai
  • Economy
    • Aviation
  • Tech
    • Mobiles
    • Apps
  • Auto
    • Cars
    • Bikes
  • Markets
    • Commodities
    • Currency
  • Railways
  • World
    • Economy
    • Politics
    • Markets
  • Survey
  • videos
  • photos
  • More ...
    • VIDEOS
    • PHOTOS
BREAKING NEWS
  • Dalal Street Corner: Market ends flat even as FII selling nears exhaustion; what should investors do on Friday?
  • Exclusive: June GST collections estimated at Rs 1.37-1.39 lakh cr, sources tell Zee Business ahead of announcement on 1 July
  • Eknath Shinde sworn in as 30th Chief Minister of Maharashtra, Fadnavis becomes Deputy CM
  • Gold Price Today: Weaker Rupee to hold yellow metal slide domestically, amid strengthening Dollar; analyst suggests strategy
  • Monsoon session of Parliament to begin on July 18; to end on August 12
Read in App
Business News » World News

Roche 'steps up' for gene therapy with $4.3 bln Spark bet

  • Twitter
  • Facebook
  • Linkedin
  • whatapp
  • View in App

Roche is buying U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion after developments in this area convinced the Swiss drugmaker to "step up", Chief Executive Severin Schwan said on Monday.

Roche will pay $114.50 per share for Spark, more than twice the U.S. company`s closing price on Feb. 22, for a portfolio that includes a blindness treatment that has U.S. and European approval and other projects for haemophilia and neurodegenerative disorders like Huntington`s disease.

Basel-based Roche is buying Spark as rivals, including Novartis, also move aggressively into gene therapy, where treatments for rare, inherited diseases command some of the highest prices in medicine. Spark`s blindness therapy Luxturna is priced at $850,000 per patient.

"We`ve been watching this space for quite some time. We just feel it`s now the right time to step up," Schwan told Reuters in an interview.

"The fit of Spark and Roche is really excellent. It provides us with a broad portfolio, it provides us with expertise across the value chain."

Schwan is counting on new medicines, including gene therapies, to help compensate for patent losses on his $21-billion-per-year trio of cancer medicines Rituxan, Herceptin and Avastin, that are facing competition from cheaper copies.

Roche, the biggest cancer drugs maker, was late to the game in immuno-oncology where Merck`s Keytruda is becoming the dominant player and has eclipsed Roche`s own product, Tecentriq, that seeks to harness the body`s immune system to fight cancer.

Bank Vontobel analysts said the Spark deal gives Roche a proven platform for commercialising gene therapies, but did not come without risks -- including getting beaten to market by rivals with similar treatments in the works.

Roche shares were 0.4 percent lower by 1140 GMT.

Gene therapies use specially engineered viruses, or viral vectors, to deliver genetic material into defective cells, in hopes of improving or potentially even curing an inherited condition.

Luxturna, sold in the United States by Spark and elsewhere by Novartis after its approval in 2017, targets a rare genetic disease, Leber`s congenital amaurosis, that causes blindness in about 1 in 200,000 people.

Loss-making Spark had $51.6 million in revenue in the first nine months of 2018 from Luxturna and also had income from a deal with Pfizer, which it is partnering on another gene therapy for haemophilia B.

Philadelphia-based Spark`s shares are up about 30 percent this year. The U.S.-company`s stock tumbled last year after two of 12 patients showed an unfavourable immune response when treated with a higher dose of Spark`s haemophilia therapy SPK-8011.

Schwan said Roche was satisfied that the issues that emerged could be addressed with steroid treatment.HEAD START

Roche`s Spark deal, seen closing in the second quarter, follows Novartis`s $8.7 billion purchase of U.S.-based Avexis last year, also to gain a platform of gene therapies for disorders including spinal muscular atrophy.

Novartis has made gene therapy one of its focus areas, giving it a head start on Roche. U.S. approval of Novartis`s SMA medicine is slated for coming months.

Among Spark`s top drug hopefuls is SPK-8011, for haemophilia A, expected to start Phase 3 trials in 2019. It is also working on treatments for Pompe disease, blindness-causing choroideremia and Huntington`s disease.

"The needs of patients and families living with genetic diseases are immediate and their needs vast," Spark Chief Executive Jeffrey Marrazzo said.

Roche already sells Hemlibra against haemophilia A that helps stop bleeding in patients with the genetic disorder that prevents their blood from clotting. Hemlibra, approved in 2017, had 224 million Swiss francs ($224.18 million) in sales last year.

Schwan said he was not worried about gene therapy and Hemlibra cannibalising sales from each other. "Our best guess is, it is complementary and that actually patients will need both options -- a medicine like Hemlibra, and increasingly over time, gene therapy," he said.

With Spark, Roche enters a crowded haemophilia gene therapy market, as other players - Biomarin Pharma, Uniqure NV and Sangamo Therapeutics - also have gene therapies in the works.

"We view Biomarin likely first to market," Vontobel analyst Stefan Schneider said. "We view the market opportunity big enough to accommodate more than one gene therapy - but a favourable safety profile will likely win gold."($1 = 0.9992 Swiss francs)

(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.

TAGS:
Economy
Updated: Mon, Feb 25, 2019
11:59 pm
Reuters
RELATED NEWS
US stocks see worst first half drop in over 50 years US stocks see worst first half drop in over 50 years
Rupee hits record low of 79.11 against US dollar in early trade Rupee hits record low of 79.11 against US dollar in early trade
Retail inflation for industrial workers rises to 6.97% in May Retail inflation for industrial workers rises to 6.97% in May
GST Council Meeting: Full details of goods and services, where rates hiked or slashed GST Council Meeting: Full details of goods and services, where rates hiked or slashed
HDFC NIMs to be under pressure for a quarter: Parekh HDFC NIMs to be under pressure for a quarter: Parekh

LATEST NEWS

2022 Maruti Suzuki BREZZA: Maruti Suzuki launches New Brezza today, Check price, features, and more

Apple iPhone users can transfer any data from Android 12 phones - Check details

GST Council Meeting Outcome: Big boost for Rakesh Jhunjhunwala's stock as sewage treated water gets exemption from GST

Stock Market Outlook: Our dependence on US market limited now, next 10-15 years belong to India, says Anil Singhvi | Here's why

Covid-19 Report: Active Covid cases rise to 1,07,189 in-country

PAN-Aadhaar Link: Don't know if your PAN linked with Aadhaar? Check steps here now or else pay double penalty from July 1

Byju's lays-off 500 employees; employees contest company's claim, says number is higher

HSBC to relaunch India private banking business within a year, says India CEO

PNB Housing Fin to seek shareholders' nod next month to raise Rs 12,000 crore in debt

Eknath Shinde sworn in as 30th Chief Minister of Maharashtra, Fadnavis becomes Deputy CM

  • India News
  • World News
  • Companies News
  • Market News
  • Personal Finance News
  • Technology News
  • Automobile News
  • Small Business News
  • Income Tax Calculator
  • Live TV
  • Videos
  • Photos
  • Author
  • Rss Feed
  • Advertise with us
  • Privacy Policy
  • Legal Disclaimer

Latest Trending Updates

  • EPFO
  • Budget 2020
  • Income Tax Return
  • Auto Expo 2020
  • Home Loan
  • Business News

Trending Topics

  • Income Tax
  • income Tax Calculator
  • 7th Pay Commission
  • Reserve Bank of India
  • GST
  • Latest Business News

Follow us on

zeebiz
zeebiz

Partner Sites

  • Zee News
  • Hindi News
  • Marathi News
  • Bengali News
  • Tamil News
  • Malayalam News
  • Gujarati News
  • Telugu News
  • Kannada News
  • DNA
  • WION
© 2022. India Dot Com Private Limited. All Rights Reserved.
LIVE TV